Less can be more: the impact of chemotherapy on cutaneous T-cell lymphomas

Future Oncology

Volumn 9, Issue 8, 2013, Pages 1061-1064

  Dummer, Reinhard ^a   Rozati, Sima ^a   Guenova, Emmanuella ^a   Cozzio, Antonio ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

bexarotene; chemotherapy; cutaneous T cell lymphoma; HDAC inhibitor; immunotherapy; stem cell transplantation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BEXAROTENE; BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; INTERFERON; METHOTREXATE; MOGAMULIZUMAB; PREDNISOLONE; PREDNISONE; VINCRISTINE; VINCRISTINE SULFATE; ZANOLIMUMAB;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; COMBINATION CHEMOTHERAPY; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; FATIGUE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; IMMUNOMODULATION; LARGE CELL LYMPHOMA; LOW DRUG DOSE; NAUSEA; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; DRUG THERAPY; HUMANS; IMMUNOTHERAPY; LYMPHOMA, T-CELL, CUTANEOUS; STEM CELL TRANSPLANTATION;

EID: 84881273717     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.87     Document Type: Review

References (24)

1. Willemze R. Cutaneous T-cell lymphoma: Epidemiology, etiology, and classification. Leuk. Lymphoma 44 (Suppl. 3), S49-S54 (2003).
2. Olsen E, Vonderheid E, Pimpinelli N et al.Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110 (6), 1713-1722 (2007).
3. Kim YH, Willemze R, Pimpinelli N et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110 (2), 479-484 (2007).
4. Olsen EA, Whittaker S, Kim YH et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J. Clin. Oncol. 29 (18), 2598-2607 (2011).
5. Knobler R, Burg G, Whittaker S, Baila L. EORTC cutaneous lymphoma task force. European Organisation for Research and Treatment of Cancer. Eur. J. Cancer 38 (Suppl. 4), S60-S64 (2002).
6. Dummer R, Dreyling M. Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 19 (Suppl. 2), ii72-ii76 (2008).
7. Belloni B, Johansen N, Glass LF, Dummer R. Recent advances in the management of cutaneous lymphomas. Semin. Oncol. 39 (2), 150-162 (2012).
8. Dummer R, Quaglino P, Becker JC et al. Prospective international multicenter Phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: Final results from EORTC 21012. J. Clin. Oncol. 30 (33), 4091-4097 (2012).
9. Jidar K, Ingen-Housz-Oro S, Beylot-Barry M et al. Gemcitabine treatment in cutaneous T-cell lymphoma: A multicentre study of 23 cases. Br. J . Dermatol. 161 (3), 660-663 (2009).
10. Thomas ED, Lochte HL Jr, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N. Engl. J. Med. 257 (11), 491-496 (1957).
11. Horwitz SM, Olsen EA, Duvic M, Porcu P, Kim YH. Review of the treatment of mycosis fungoides and Sezary syndrome: A stage-based approach. J. Natl Compr. Canc. Netw. 6 (4), 436-442 (2008).
12. Koeppel MC, Stoppa AM, Resbeut M et al.Mycosis fungoides and allogenic bone marrow transplantation. Acta Derm. Venereol. 74 (4), 331-332 (1994).
13. Schlaak M, Theurich S, Pickenhain J, Skoetz N, Kurschat P, von Bergwelt-Baildon M. Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: A systematic review. Crit. Rev. Oncol. Hematol. 85 (1), 21-31 (2013).
14. Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst. Rev. 1, CD008908 (2012).
15. Duarte RF, Schmitz N, Servitje O, Sureda A. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant. 41 (7), 597-604 (2008).
16. Duarte RF, Canals C, Onida F et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: A retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol. 28 (29), 4492-4499 (2010).
17. Wysocka M, Dawany N, Benoit B et al. Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-gamma: Implications for therapy of cutaneous T-cell lymphoma. Leuk. Lymphoma 52 (10), 1970-1979 (2011).
18. Guenova E, Watanabe R, Desimone JA et al. Th2 cytokines from malignant cells suppress Th1 responses and enforce a global Th2 bias in leukemic cutaneous T cell lymphoma. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-12-3488 (2013) (Epub ahead of print).
19. Clark RA, Watanabe R, Teague JE et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci. Transl. Med. 4 (117), 117ra117 (2012).
20. Duvic M, Hymes K, Heald P et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational Phase II-III trial results. J. Clin. Oncol. 19 (9), 2456-2471 (2001).
21. Assaf C, Bagot M, Dummer R et al. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: An expert opinion. Br. J . Dermatol. 155 (2), 261-266 (2006).
22. Kelly-Sell MJ, Kim YH, Straus S et al. The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. Am. J. Hematol. 87 (4), 354-360 (2012).
23. Song W, Tai YT, Tian Z et al. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. Leukemia 25 (1), 161-168 (2011).
24. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21 (1), 103-107 (1999).